Beijing AnlongBio is a clinical stage biotech in gene therapy and siRNA drug development. Its gene therapy products for ophthalmic wet macular degeneration(wAMD) and diabetic retinopathy(DR) is currently in Phase II clinical trials, making it the first gene therapy product expressing Aflibercept administered via the suprachoroidal space. Leveraging its siRNA technology platform, AnlongBio has developed several siRNA drugs targeting metabolic disorders, diabetes, ophthalmology, weight loss, neurology, and muscular diseases. AnlongBio actively pursues product and market collaborations with domestic and international pharmaceutical companies. Known for its efficiency, market orientation, and execution capabilities, AnlongBio is committed to developing affordable innovative drugs for the global market.